2020 ASCO Virtual Direct™ Highlights


 

2020 ASCO Highlights on ER+ MBC: Fulvestrant vs. Letrozole + Palbociclib in the First-line Setting - Is There an Optimal Endocrine Backbone for CDK4/6? Can Genomic Alterations Help Predict Responsiveness?

357 views
July 16, 2020
Comments 0
Login to view comments. Click here to Login